ID Design Press, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. https://doi.org/10.3889/oamjms.2018.087 eISSN: 1857-9655 *Clinical Science*



Dynapenia and Sarcopenia as a Risk Factor for Disability in a Falls and Fractures Clinic in Older Persons

Angela-María Benjumea¹, Carmen-Lucía Curcio¹, Gustavo Duque^{2,3}, Fernando Gómez^{1,3*}

¹Research Group on Geriatrics and Gerontology, Faculty of Health Sciences, International Association of Gerontology and Geriatrics Collaborative Centre, University of Caldas, Manizales, Colombia; ²Australian Institute for Musculoskeletal Science (AIMSS), Melbourne Medical School - Western Precinct, The University Of Melbourne & Western Health, Melbourne, Australia; ³Ageing Bone Research Program, Sydney Medical School Nepean, The University of Sydney, Penrith, Australia

Abstract

Citation: Benjumea AM, Curcio CL, Duque G, Gómez F. Dynapenia and Sarcopenia as a Risk Factor for Disability in a Falls and Practures Clinic in Older Persons. Open Access Maced J Med https://doi.org/10.3889/coamins_2018.087 AIM: This study aims to compare the association of sarcopenia and dynapenia with physical and instrumental

Access Maded JSC. Material Sci. Material Sci

METHODS: This is a cross-sectional study in Manizales, Andes Mountains, Colombia. A cohort of 534 subjects (mean age = 74, 75% female) Sarcopenia was measured according to the European Working Group on Sarcopenia in Older People (EWGSOP) including an index of skeletal mass, muscle strength, and gait speed. Dynapenia was defined as a handgrip force \leq 30 kg for men and \leq 20 kg for women.

RESULTS: Dynapenia and sarcopenia were present in 84.6% and 71.2% respectively. Both were more prevalent in older subjects and women than men. While sarcopenia was associated with body mass index and hypertension, dynapenia was associated with hypothyroidism and visual impairment. After controlling for all covariates, sarcopenia was associated with low IADL and mobility disability.

CONCLUSIONS: Sarcopenia was associated with mobility, ADL and IADL disability. Dynapenia was not associated with disability in this high - risk population. Systematic assessment of sarcopenia should be implemented in falls and fractures clinics to identify sarcopenia and develop interventions to prevent functional decline among elderly individuals.

Funding: This study was supported by a grant from Vicerrectoria de Investigaciones from the University of Caldas (Manizales, Colombia). Another support was an Australian Government Overseas Aid Program (AusAID) to Dr Gomez and a grant from the Nepean Medical Research Foundation to Professor Duque **Competing Interests:** The authors have declared that no competing interests exist

*Correspondence: Fernando Gómez, Research Group on Geriatrics and Gerontology, Faculty of Health Sciences, International Association of Gerontology and Geriatrics Collaborative Centre, University of Caldas, Manizales, Golombia. E-mail: gomez.montes@ucaldas.edu.co

Received: 19-Nov-2017; Revised: 14-Dec-2017; Accepted: 26-Dec-2017; Online first: 14-Feb-2018

Copyright: © 2018 Angela-María Benjumea, Carmen-Lucía Curcio, Gustavo Duque, Fernando Gómez. This is an open-access article distributed under the terms of the Creative Commons Artitibution-NonCommercial 4.0 International License (CC BY-NC 4.0)

Introduction

Sarcopenia has been defined as a loss of muscle mass and muscle strength related to ageing. [1][2]. However, there are divergences about the mechanisms, definitions and measurements of sarcopenia. The main point of discussion is the inclusion of muscle mass and strength in the same concept because the decline in muscle strength can be attributed to a combination of muscular and neural factors and not only to reduced muscle mass [3]. At the same time, recent data from longitudinal studies on ageing indicate that maintaining or gaining muscle mass does not prevent aging-related decline in muscle strength [4][5]. Dynapenia (Greek translation

for the poverty of strength, power, or force) is the ageassociated loss of muscle strength that is not caused by neurologic or muscular diseases [6]. Low muscle strength is well known to place older adults at an increased risk of mobility limitations and mortality [6]. Accordingly, the preservation of muscle strength and power with advancing age is of high clinical significance.

Since dynapenia is only partially explained by the reduction in muscle mass (sarcopenia), several authors insist that these two conditions need to be defined independently of one another [7]. However, The European Working Group on Sarcopenia in Older People (EWGSOP) recommendations for a diagnosis of sarcopenia, which is widely disseminated in clinical practice, includes not only the presence of low muscle mass (LMM) but also low muscle strength (LMS) and/or low physical performance (LPP) [8]. Recent studies have highlighted the relationship between sarcopenia and falling [9][10]. Indeed, we previously identified a phenotype of osteosarcopenia in older individuals with a history of falling in a fall and Fractures Clinic in Australia [11]. However, the role of sarcopenia and dynapenia in disability in this high-risk population remains unexplored.

Also, few studies have been carried on in Latin America about sarcopenia o dynapenia as a predictor of disability [12][13].

Therefore, the present study aims to compare the association of disability with either EWGSOP defined sarcopenia or dynapenia in a high - risk population of older fallers in Colombia.

Materials and Methods

Study population

This is cross-sectional study. The setting was the Falls, Dizziness, and Fractures Clinic at University of Caldas (Manizales, Andes Mountains, Colombia, South America). The participants were 534 subjects (mean age = 74, 75% female) assessed between January 2002 - 2014. To be included in the study, participants had to be at least 60 years old and have a complete data set. Participants were excluded based on severe medical conditions that may significantly affect their mobility or incomplete registration of data.

Eligibility criteria to attend the falls, dizziness and fractures clinic included ability to mobilize with a walker or cane(s), willingness to attend the clinic, and at least one of the following: multiple faller (more than two in the last year), single faller with established gait and/or balance problem (e.g., by Get Up and Go Test), unexplained fall with apparent complex medical cause(s), history of chronic dizziness (last 5 years and no earlier than 3 months) and/or history of self reported symptomatic or asymptomatic fragility fracture(s). The University of Caldas Ethics Research Committee approved this study.

Dependent variables: disability

Respondents were asked if they had difficulty performing activities of daily living (ADL) using a Spanish version of the Barthel ADL scale [14]. If the respondents indicated difficulty or inability in performing one or more of the tasks, they were scored as having ADL disability. Despite its importance about functionality in elderly individuals, incontinence was not included in ADL because it does not necessarily imply physical limitation [15]. For the instrumental activities of daily living (IADL), respondents were asked if they were able to perform eight activities (using a telephone, shopping, preparing meals, performing light housework, taking medications, managing money, doing heavy housework and using transportation), using a modified Spanish version of the Lawton IADL scale [16]. If respondents indicated difficulty or inability in performing one or more of the tasks, they were scored as having IADL disability. A summary score for mobility, ADL and IADL variables was computed. The final disability variable was hierarchical, with three levels. A score of 0 indicated no mobility, ADL or IADL limitation; 1 indicated any IADL limitation or a mobility limitation, and 2 indicated IADL and ADL limitations [17].

Independent Variables

Muscle mass was estimated by appendicular skeletal muscle mass (ASM) using the Lee equation as follow [18]: ASM = (0.244 * body weight) + (7.8 * height) + (6.6 * gender) - (0.098 * age) + (race - 3.3). Body weight was measured in kilograms (kg), and height was measured in meters. This equation has been validated in older population from Latin America using dual-energy X-ray absorptiometry (DXA) as a gold standard with a high correlation between methods (r = 0.86 for men and r = 0.90 for women, respectively, p < 0.05) [19]. After estimating the values, we adjusted the ASM by height squared to create the skeletal muscle mass index (SMI).

Following the studies of Delmonico et al. [20] and Newman et al. [21], the cutoff for LMM used was based on the 20% lowest percentile of the population distribution, representing SMI of ≤ 6.37 kg/m² for women and ≤ 8.90 kg/m² for men. Muscle strength was assessed with handgrip strength in kg using a hand-held dynamometer (Takey hvdraulic dynamometer, the Smedley Hand Dynamometer III). Grip size was adjustable so that each participant felt comfortable while squeezing the grip. The test was performed twice in the dominant limb with a 1 - minute rest between tests and the higher value of the two trials was used for scoring. Cutoff values of < 30 kg for men and < 20 kg for women were considered to represent Low Muscle Strength [8][22].

The Spanish validated the version of Physical performance was assessed with gait speed (in meters/second), determined using the walk test of the Short Physical Performance Battery assessing Lower Extremity Function. The faster of the two trials was used for analyses [23]. The cut - off point of ≤ 0.8 m/s was used to represent LPP [8][22].

Sarcopenia was defined using the EWGSOP criteria. Participants with LMM plus either LMS or LPP were considered as having sarcopenia [8]. Dynapenia was defined using the criteria of Laurentani et al. [22]: < 30 kg for men and < 20 kg for women.

Covariates

Demographic characteristics were age. gender, marital status and education. Education was measured as years of formal schooling completed and was analysed as a continuous variable. (range, 0 to 18). Health status variables included perceived health status, chronic conditions, visual and auditory impairment, depression and cognitive status. The presence of seven chronic conditions (osteoarthritis, hypertension, diabetes mellitus, stroke, chronic obstructive pulmonary disease, and hypothyroidism) was ascertained through self - report. Physical performance was assessed with gait speed (in meters/second), determined using the walk test of the Short Physical Performance Battery Assessing Lower Extremity Function [23]. The faster of the two trials was used for analyses. The cut - off point of ≤ 0.8 m/s used to represent LPP [8]. Falls was and hospitalisations in the previous 12 months were assessed. Sensory impairments were assessed by asking for troubles with vision and hearing (yes or no). Cognition was assessed by the Mini-Mental State Examination; participants with a score of less than 20 were considered to be cognitively impaired [24][25]. An abbreviated (score 0 to 15) Spanish-validated Geriatric Depression Scale (GDS - S) was used to assess the presence of depressive symptoms [26]: respondents with a score of 6 or more on GDS - S are considered likely to be depressed. Body mass index (BMI) was computed by dividing weight in kilograms by height in square meters (kg/m²).

Statistical analyses

The characteristics of the participants were described by means and standard deviations (SD) or frequencies and percentages according to the type of variable (continuous or categorical, respectively). The chi-square test was used to test qualitative data, while analysis of variance (ANOVA) was used to evaluate continuous data. Statistical differences between groups were determined. To identify the factors associated with disability, variables were selected based on the strength of the associations, higher prevalence (10% or more), clinical relevance, and low potential for collinearity. We calculated OR and 95% confidence intervals (CI). A three-step procedure was developed. First, univariate logistic regression analyses were used to describe the unadjusted effect of sarcopenia and dynapenia and covariates, in the second step, multivariate linear regression models were created to adjust by potential confounder covariates. Based on previous results, we proceeded with multivariate analysis using multiple multinomial logistic regressions, which estimates the prevalence odds ratios (OR). Model 1 includes sarcopenia as an independent variable and model 2 includes dynapenia. Statistical analyses were performed using SPSS for Windows version 22.0.

The mean age ± standard deviation of the participants was 74.4 ± 8.2 years; 75.5% were female, 41.1% were married and the mean years of scholarly were 6.2 ± 4.4 . The most prevalent medical conditions were hypertension (65.9%), hypothyroidism (21.9%) and diabetes (15.5%). Sarcopenia and dynapenia were present in 84.6% and 71.2% of the participants, respectively. Table 1 shows the baseline characteristics of the total sample and by sarcopenia and dynapenia status. Participants with sarcopenia and dynapenia were significantly more likely to be older. Those with dynapenia were more female and reported more hypothyroidism, falls and visual impairments, while those with sarcopenia had lower BMI and reported more hypertension. Visual and auditory impairments were reported by 80.4 % and 49.3% of the participants, respectively.

Table 1: Characteristics of the total sample and by sarcopenia and dynapenia status at baseline in clinic of fractures, falls and dizziness

$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
	Characteristic		Sarcopenia N = 154	Sarcopenia N = 380	Dynapenia N = 452	Dynapenia N = 82
Age, mean (DE)74.4 (8.2)74 (7.9)*76 (8.3)*75.9 (8.1)**72.6 (8.6)**80 or more yeas (%)173 (32.4)42 (27.3)131 (34.5)156 (34.5)17 (20.7)Women (%)403 (75.5)117 (76)286 (75.3)364 (80.5)**39 (47.6)**Schooling (years)6.24 (4.4)5.9 (4.2)6.4 (4.5)6.4 (4.4)*5.5 (4.4)*Marital status (single)77 (14.4)15 (9.7)62 (16.3)72 (15.9)5 (6.1)Self perceived health73 (13.8)22 (14.2)51 (13.6)61 (13.7)12 (14.6)Bad /very bad (%)73 (13.8)22 (14.2)51 (13.6)61 (13.7)12 (14.6)Health conditions114 (75)**230 (62.2)**294 (66.5)50 (62.5)Cancer26 (5)8 (5.3)18 (4.9)23 (5.2)3 (3.8)Stroke43 (8.4)18 (12.1)25 (6.9)39 (9)4 (5)Diabetes (yes)33 (6.3)8 (5.3)25 (6.7)29 (65.5)4 (5)Hipothiroidism115 (21.9)42 (27.5)73 (19.7)108 (24.3)**7 (8.8)**COPD255 (10.7)13 (8.7)42 (11.4)48 (11)7 (8.8)**Falls in last year (yes)309 (60.4)122 (79.7)304 (80.6)370 (82.4)**56 (69.1)**Hearing impairment (yes)426 (80.4)122 (79.7)304 (80.6)370 (82.4)**56 (69.1)**Hearing impairment (yes)66 (12.4)14 (9.1)52 (13.7)59 (13.1)7 (8.5)Ogy (55 > 26 (7.0)28 (6.9)76	Sociodemographics		()	(0.1.0)	()	(====)
$ \begin{array}{l l l l l l l l l l l l l l l l l l l $	Age, mean (DE) 80 or more years (%) Women (%)	173 (32.4) 403 (75.5)	42 (27.3) 117 (76)	131 (34.5) 286 (75.3)	156 (34.5) 364 (80.5)**	17 (20.7) 39 (47.6)**
		6.24 (4.4)	5.9 (4.2)	- (-)	- ()	5.5 (4.4)*
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Marital status (single)	77 (14.4)	15 (9.7)	62 (16.3)	72 (15.9)	5 (6.1)
$\begin{array}{c ccccc} \mbox{Hipertension (yes)} & 344 (65.9) & 114 (75)^{**} & 230 (62.2)^{**} & 294 (66.5) & 50 (62.5) \\ \mbox{Cancer} & 26 (5) & 8 (5.3) & 18 (4.9) & 23 (5.2) & 3 (3.8) \\ \mbox{Stroke} & 43 (8.4) & 18 (12.1) & 25 (6.9) & 39 (9) & 4 (5) \\ \mbox{Diabetes (yes)} & 81 (15.5) & 31 (20.3) & 50 (13.5) & 73 (16.4) & 8 (10) \\ \mbox{Osteoartriks (yes)} & 33 (6.3) & 8 (5.3) & 25 (6.7) & 29 (6.5) & 4 (5) \\ \mbox{Hipothinoidism} & 115 (21.9) & 42 (27.5) & 73 (19.7) & 108 (24.3)^{**} & 7 (8.8)^{**} \\ \mbox{COPD} & (55 (11.4) & 48 (11) & 7 (8.8) & 7 (8.8)^{**} \\ \mbox{Falls in last year (yes)} & 309 (60.4) & 216 (59.5) & 93 (62.4) & 261 (72.7)^{*} & 38 (47.5)^{*} \\ \mbox{Hospitalization last year} & 289 (54.1) & 80 (51.9) & 209 (55) & 246 (54.4) & 43 (52.4) \\ \mbox{Vision impairment (yes)} & 426 (80.4) & 122 (79.7) & 304 (80.6) & 370 (82.4)^{**} & 56 (69.1)^{**} \\ \mbox{Vision impairment (yes)} & 426 (80.4) & 122 (79.7) & 304 (80.6) & 370 (82.4)^{**} & 56 (69.1)^{**} \\ \mbox{Vision impairment (yes)} & 426 (80.4) & 122 (79.7) & 304 (80.6) & 370 (82.4)^{**} & 56 (69.1)^{**} \\ \mbox{Vision impairment (yes)} & 66 (12.4) & 14 (9.1) & 52 (13.7) & 59 (13.1) & 7 (8.5) \\ \mbox{Cognitive status} & 66 (12.4) & 14 (9.1) & 52 (13.7) & 59 (13.1) & 7 (8.5) \\ \mbox{Depressive symptoms} & 233 (43.4) & 76 (49.4) & 156 (41.1) & 205 (45.4) & 27 (32.9) \\ \mbox{GDS > 5 (n \%) & Physical performance} \\ \mbox{(SPPB)} & 0.80 (0.99) & 0.91 (1.15)^{**} & 0.54 (0.17)^{**} & 0.73 (0.62)^{*} & 1.18 (2.03)^{*} \\ \mbox{Call Solution (Misser)} & 0.80 (0.99) & 0.91 (1.15)^{**} & 0.54 (0.17)^{**} & 0.73 (0.62)^{*} & 1.18 (2.03)^{*} \\ \mbox{Call Solution (Misser)} & 0.80 (0.99) & 0.91 (1.15)^{**} & 0.54 (0.17)^{**} & 0.73 (0.62)^{*} & 1.18 (2.03)^{*} \\ \mbox{Call Solution (Misser)} & 0.80 (0.99) & 0.91 (1.15)^{**} & 0.54 (0.17)^{**} & 0.73 (0.62)^{*} & 1.18 (2.03)^{*} \\ \mbox{Call Solution (Misser)} & 0.80 (0.99) & 0.91 (1.15)^{**} & 0.54 (0.17)^{**} & 0.73 (0.62)^{*} & 0.54 (0.5)^{*} \\ \mbox{Call Solution (Misser)} & 0.80 (0.99) & 0.91 (1.15)^{**} & 0.$	Bad /very bad (%)	73 (13.8)	22 (14.2)	51 (13.6)	61 (13.7)	12 (14.6)
$ \begin{array}{cccc} Cancer & 26 (5) & 8 (5.3) & 18 (4.9) & 23 (5.2) & 3 (3.8) \\ Stroke & 43 (8.4) & 18 (12.1) & 25 (6.9) & 39 (9) & 4 (5) \\ Diabetes (yes) & 81 (15.5) & 31 (20.3) & 50 (13.5) & 73 (16.4) & 8 (10) \\ Osteoartritis (yes) & 33 (6.3) & 8 (5.3) & 25 (6.7) & 29 (6.5) & 74 (6.8) ** \\ Hipothiroidism & 115 (21.9) & 42 (27.5) & 73 (17.1) & 108 (24.3) ** & 74 (8.8) ** \\ COPD & 55 (10.7) & 13 (8.7) & 42 (11.4) & 48 (11) & 7 (8.8) ** \\ CoPD & 55 (10.7) & 13 (8.7) & 42 (11.4) & 48 (11, 7 (8.8) ** \\ Hospitalization last year & 289 (56.4) & 216 (59.5) & 23 (62.4) & 261 (72.7) * 38 (47.5) * \\ Hospitalization last year & 289 (56.4) & 80 (51.9) & 209 (55) & 246 (54.4) & 43 (52.4) \\ V(sison impairment (yes) & 426 (80.4) & 122 (79.7) & 304 (80.6) & 370 (82.4) ** & 56 (69.1) ** \\ Hearing impairment (yes) & 255 (49.3) & 76 (50.7) & 179 (48.8) & 207 (47.4) * & 48 (60) * \\ (yes) & 056 (24.1) & 30.3 (6.7) ** & 24.2 (6.4) ** & 25.6 (7.06) & 28 (6.9) \\ Cognitive status & 66 (12.4) & 14 (9.1) & 52 (13.7) & 59 (13.1) & 7 (8.5) \\ Depressive symptoms & 233 (43.4) & 76 (49.4) & 156 (41.1) & 205 (45.4) & 27 (32.9) \\ OBS > 5 (n \%) & Physical performance \\ (SPPB) & Ox80 (M/seg). & 0.80 (0.99) & 0.91 (1.15) ** & 0.54 (0.17) ** & 0.73 (0.62) * & 1.18 (2.03) * \\ \end{array}$						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						
$\begin{array}{c c c c c c c c c c c c c c c c c c c $						
		115 (21.9)	42 (27.5)	73 (19.7)	108 (24.3) **	7 (8.8) **
$\begin{array}{c} \mbox{Hospitalization last year} \\ \mbox{(yes)} \\ \mbox{Hospitalization last year} \\ \mbox{(yes)} \\ \mbox{Hearing impairment} \\ \mbox{(yes)} \\ \mbox{Hearing impairment} \\ \mbox{(yes)} \\ \mbox{BMI: mean (DE)} \\ \mbox{26} (7.1) \\ \mbox{30} (6.7) \\ \mbox{27} (7.7) \\ \mbox{30} (6.7) \\ \mbox{37} (48.8) \\ \mbox{207} (47.4)^* \\ \mbox{48} (60)^* \\ \mbox{48} (60)^* \\ \mbox{29} (13.7) \\ \mbox{59} (13.7) \\ \mbox{59} (13.7) \\ \mbox{59} (13.1) \\ \mbox{7} (8.5) \\ \mbox{Depressive symptoms} \\ \mbox{203} (43.4) \\ \mbox{76} (49.4) \\ \mbox{156} (41.1) \\ \mbox{205} (45.4) \\ \mbox{27} (32.9) \\ \mbox{C9S} (5.7) \\ \mbox{50} (13.7) \\ \mbox{59} (13.7) \\ \mbox{59} (13.1) \\ \mbox{7} (8.5) \\ \mbox{Physical performance} \\ \mbox{(SPPB)} \\ \mbox{Gait Speed} (M/seg). \\ \mbox{0,80} (0.99) \\ \mbox{0.91} (1.15)^{**} \\ \mbox{0.54} (0.17)^{**} \\ \mbox{0.54} (0.17)^{**} \\ \mbox{0.73} (0.62)^{*} \\ \mbox{1.18} (2.03)^{*} \\ \mbox{1.18} (2.0$						
	Falls in last year (yes)	309 (60.4)	216 (59.5)	93 (62.4)	261 (72.7)*	38 (47.5)*
Hearing impairment (yes) 255 (49.3) 76 (50.7) 179 (48.8) 207 (47.4)* 48 (60)* BMI: mean (DE) 26 (7.1) 30.3 (6.7)** 24.2 (6.4)** 25.6 (7.06) 28 (6.9) Cognitive status 66 (12.4) 14 (9.1) 52 (13.7) 59 (13.1) 7 (8.5) Depressive symptoms 233 (43.4) 76 (49.4) 156 (41.1) 205 (45.4) 27 (32.9) OBS > 5 (n %) Physical Performance (SPPB) 0.80 (0.99) 0.91 (1.15)** 0.54(0.17)** 0.73 (0.62)* 1.18 (2.03)*		289 (54.1)	80 (51.9)	209 (55)	246 (54.4)	43 (52.4)
	Vision impairment (yes)	426 (80.4)	122 (79.7)	304 (80.6)	370 (82.4) **	56 (69.1) **
Cognitive status 66 (12.4) 14 (9.1) 52 (13.7) 59 (13.1) 7 (8.5) MMSE < 20 (%)		255 (49.3)	76 (50.7)	179 (48.8)	207 (47.4)*	48 (60)*
MMSE < 20 (%) bb (12.4) 14 (9.1) 7 (8.5) Depressive symptoms 233 (43.4) 76 (49.4) 156 (41.1) 205 (45.4) 27 (32.9) GDS > 5 (n %) Physical performance (SPPB) 0.80 (0.99) 0.91 (1.15)** 0.54(0.17)** 0.73 (0.62)* 1.18 (2.03)*	BMI: mean (DE)	26 (7.1)	30.3 (6.7) **	24.2 (6.4) **	25.6 (7.06)	28 (6.9)
GDS > 5 (n %) Physical performance (SPPB) Gait Speed (M/seg). 0,80 (0.99) 0.91 (1.15)** 0.54(0.17)** 0.73 (0.62)* 1.18 (2.03)*		66 (12.4)	14 (9.1)	52 (13.7)	59 (13.1)	7 (8.5)
Physical performance (SPPB) Gait Speed (M/seg). 0,80 (0.99) 0.91 (1.15)** 0.54(0.17)** 0.73 (0.62)* 1.18 (2.03)*	Depressive symptoms	233 (43.4)	76 (49.4)	156 (41.1)	205 (45.4)	27 (32.9)
mean (DE)	Physical performance (SPPB) Gait Speed (M/seg).	0,80 (0.99)	0.91 (1.15)**	0.54(0.17)**	0.73 (0.62)*	1.18 (2.03)*
	mean (DE)					

* P<0.05; **P<0.01.

In the bivariate analysis, there were strong associations between dynapenia and age (OR = 1.06, 95% CI = 1.01 - 1.11, p = 0.01), sex (OR = 1.16, 95% CI=1.16 - 1.31, P < 0.01), hypothirodism (OR = 6.09, 95% CI = 1.56 - 23.7, p < 0.01) and visual impairment (OR = 2.21 (1.03 - 4.75, p < 0.01). While significant associations were noted between sarcopenia and age (OR = 1.04, 95% CI = 1.0 - 1.08, p < 0.01), sex (OR = 1.37, 95% CI = 1.00 - 2.51, p = 0.29) and BMI (OR = 1.02, 95% CI = 1.0 - 1.09, p < 0.01).

Table 2 presents the weighted multinomial regression analysis for disability. In model 1, the following were risk factors for incidence in mobility or IADL disability: age and sarcopenia; some falls had a marginal statistical relationship. The risk factors for

ADL and IADL disability were: age, female and sarcopenia. In model 2 the same risk factors were found. However, dynapenia was not associated with disability.

Table 2: Weighted multinomial regression analysis for disability

	Mobility or IADL	ADL and IADL	Mobility or	ADL and IADL
	Sarcopenia	Sarcopenia	IADL	Dynapenia
	model	model	Dynapenia	model
	N = 259	n= 144	model	n= 192
	OR (95%)	OR (95%)	n= 332	OR (95%)
	. ,	. ,	OR (95%)	. ,
Age	1.09	1.12	1.08	1.11
-	(1.05–1.11)	(1.08 – 1.16)	(1.05-1.12)	(1.08 – 1.15)
Sex (female)	1.50	2.29	1.43	1.97
	(0.87 – 2.58)	(1.32 – 3.96)	(0.81 – 2.52)	(1.11 – 3.49)
Hypertension	0.67	0.78	0.63	0.71
	(0.40 – 1.12)	(0.48 – 1.27)	(0.38 – 1.04)	(0.43 – 1.15)
Hypothyroidism	1.52	1.15	1.45	1.13
	(0.83-2.80)	(0.65 – 2.03)	(0.79 – 2.66)	(0.64 – 1.98)
Falls (number)	1.01	1.06	1.02	1.06
	(0.93- 1.11)	(0.98 – 1.14)	(0.94 – 1.11)	(0.98 – 1.15)
Visual impairment	1.24	0.70	1.34	1.29
	(0.69 – 2.23)	(0.30 – 1.65)	(0.74 – 2.42)	(0.71 – 2.33)
Sarcopenia	2.03	2.03	-	-
	(1.16 - 3.53)	(1.18 – 3.50)		
Dynapenia	-	-	0.87	0.52
			(0.45-1.67)	(0.26 – 1.06)

Discussion

Sarcopenia, according to the EWGSOP, was associated with low mobility and disability. Our data correspond with those previous reports [12][27] by showing an association between LMM, LMS and LPP and IADL, mobility and ADL disability. In addition, studies in different settings as community-dwelling older people [28][29][30][31][32][33][34][35][36], acute care [37][38][39] and nursing homes [40][41] showed a significant association between sarcopenia and functional limitation and disability.

Our results also correspond with other studies in Latin America, which have demonstrated that sarcopenia is a risk factor for disability in the elderly. In a four year prospective study in 478 individuals from SABE study, founded after controlling for all covariates, Aleixandre et al., reported that sarcopenia was associated with mobility or IADL disability [12]. Similar to our results, dynapenia was not associated with disability. In another cross-sectional study in 90 hospitalised women in Mexico City, Velasquez - Alba et al., reported that sarcopenia was associated with difficulties in mobility, particular difficulties in climbing stairs [42].

To the best of our knowledge, this is the first paper testing the role of sarcopenia in the clinical measurements performed at falls and fractures clinics. The prevalence of sarcopenia is difficult to establish. The percentage of sarcopenia (84.6%) found in our study is higher than reported for older people living in the community (1-29%), for those living in long-term care institutions (14-33% and up to 68% in men), and for those in acute hospital care 10% [43]. In another study about of sarcopenia in geriatric outpatient clinics, a prevalence of sarcopenia was higher in women (22.9%) than in men (12.7%) [44]. Indeed, this prevalence can differ depending on the characteristics of the studied population and the cut off applied for measuring [45]. Our sample had a mean walk speed of 0.8 mt/sec and cut off point for EWGSOP criteria by sarcopenia case finding [8]. Another possible reason is the eligibility criteria of the sample, with complex medical problems, chronic dizziness and symptomatic or asymptomatic fragility fracture(s). Furthermore, muscle mass reflects ethnicity and lifestyle characteristics [32]. As a consequence, more data are required to determine standardised cut - off values for sarcopenia in falls and fracture clinics. However, the findings here and elsewhere [27][28][29] support the view that intervention strategies designed to preserve skeletal muscle mass should be initiated in all older people attending falls and fracture clinics.

Sarcopenia as a risk factor for falls in elderly individuals remains controversial. In this study, we could not find an association between sarcopenia (based on muscle mass) and fall number in the last year. There are conflicting reports regarding the relationship of sarcopenia with fall. Our findings are in agreement with the results of several cross-sectional surveys on sarcopenia [27][28], but other study using EWGSOP criteria examined 260 individuals aged 80 years or older in Italy found that sarcopenic individuals had a high risk of fall incidents compared with nonsarcopenic individuals [46] Another study in Japan with the same criteria examined 1160 individuals aged 65 years or older revealed that sarcopenia was significantly associated with a history of fall [9].

This study has some limitations. First, the use of the use of the regression equation to estimate muscle mass may overestimate the prevalence of sarcopenia. The availability of DXA as "gold standard" for measuring sarcopenia is limited in coffee grower zones in Colombian Andes Mountains. However, this equation has been used previously in assessing Latin American populations [18][19]. Second, the study design was cross-sectional, and the results do not establish cause-effect relationships between sarcopenia and disability and falls. Theoretically, certain types of morbidity (e.g., lung disease, stroke, and uncontrolled noninsulin - dependent diabetes mellitus) could produce sarcopenia that would result in functional impairment and disability. It is also possible that disability could lead to sarcopenia by limiting physical activity and subsequently predisposing people to some chronic diseases. Also, none of the chronic diseases was significantly associated with sarcopenia, except hypertension. Third, we used handgrip strength and usual walking speed cutoff values that were based on values derived from other reference population. Future studies are required to determine the optimal muscle strength and physical performance cutoff values for defining sarcopenia on this population.

This study has several strengths. First, it was conducted on a large sample of patients comes from falls, dizziness and fractures clinic in Latin America. Second, this study is the first to analyse sarcopenia using the EWGSOP criteria at a falls, dizziness and fracture clinic and to compare this method with dynapenia as a risk factor for mobility, IADL, disability and ADL disability.

In conclusion, sarcopenia is a risk factor for developing IADL, mobility and ADL disabilities in older people. The diagnostic criteria from (EWGSOP) using normative data should be implemented at falls and fractures clinics to identify sarcopenia and develop early interventions to prevent functional decline among this population of high-risk elderly individuals.

References

1. Evans WJ. What is sarcopenia?. J Gerontol A Biol Sci Med Sci. 1995; 50A: M5-M8.

https://doi.org/10.1093/gerona/50A.Special_Issue.5

2. Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci.2000; 55A(12): M716-M724. https://doi.org/10.1093/gerona/55.12.M716

3. Moritani T, deVries HA. Neural factors versus hypertrophy in the time course of muscle strength gain. American Journal of Physical Medicine. 1979; 58(3):115–130. PMid:453338

4. Delmonico MJ, Harris TB, Visser M, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. The American Journal of Clinical Nutrition. 2009; 90(6):1579–1585. https://doi.org/10.3945/ajcn.2009.28047 PMid:19864405 PMCid:PMC2777469

5. Clark BC, Fernhall B, Ploutz-Snyder LL. Adaptations in human neuromuscular function following prolonged unweighting: I. Skeletal muscle contractile properties and applied ischemia efficacy. Journal of Applied Physiology. 2006; 101(1):256-63. https://doi.org/10.1152/japplphysiol.01402.2005 PMid:16514004

6. Clark BC, Manini TM. What is dynapenia? Nutrition. 2012; 28(5):495–503. <u>https://doi.org/10.1016/j.nut.2011.12.002</u> PMid:22469110 PMCid:PMC3571692

 Clark BC, Manini TM. Sarcopenia =/= dynapenia. Journals of Gerontology- Series A: Biological Sciences and Medical Sciences. 2008; 63(8):829–834. <u>https://doi.org/10.1093/gerona/63.8.829</u>

 Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E. Sarcopenia: European consensus on definition and diagnosisReport of the European Working Group on Sarcopenia in Older PeopleA. J. Cruz-Gentoft et al. Age and ageing. 2010; 39(4):412-23. <u>https://doi.org/10.1093/ageing/afq034</u> PMid:20392703 PMCid:PMC2886201

9. Tanimoto Y, Watanabe M, Sun W, Sugiura Y, Hayashida I, Kusabiraki T, Tamaki J. Sarcopenia and falls in communitydwelling elderly subjects in Japan: Defining sarcopenia according to criteria of the European Working Group on Sarcopenia in Older People. Archives of gerontology and geriatrics. 2014; 59(2):295-9. https://doi.org/10.1016/j.archger.2014.04.016 PMid:24852668

10. Hita-Contreras F, Martínez-Amat A, Cruz-Díaz D, Pérez-López FR. Osteosarcopenic obesity and fall prevention strategies. Maturitas. 2015; 80(2):126-32.

https://doi.org/10.1016/j.maturitas.2014.11.009 PMid:25533145

11. Huo YR, Suriyaarachchi P, Gomez F, Curcio CL, Boersma D, Muir SW, Montero-Odasso M, Gunawardene P, Demontiero O,

Duque G. Phenotype of osteosarcopenia in older individuals with a history of falling. Journal of the American Medical Directors Association. 2015; 16(4):290-5. https://doi.org/10.1016/j.jamda.2014.10.018 PMid:25512216

12. da Silva Alexandre T, Duarte YD, Santos JF, Wong R, Lebrão ML. Sarcopenia according to the european working group on sarcopenia in older people (EWGSOP) versus Dynapenia as a risk factor for disability in the elderly. The journal of nutrition, health & aging. 2014; 18(5):547-53. <u>https://doi.org/10.1007/s12603-014-0465-9</u>

13. Velázquez Alva MD, Irigoyen Camacho ME, Delgadillo Velázquez J, Lazarevich I. The relationship between sarcopenia, undernutrition, physical mobility and basic activities of daily living in a group of elderly women of Mexico City. Nutricion hospitalaria. 2013; 28(2).

14. Baztán JJ, Pérez del Molino J, Alarcón T, San Cristóbal E, Izquierdo G, Manzarbeitia J. Índice de Barthel: instrumento válido para la valoración functional de pacientes con enfermedad cerebrovascular. Revista Espa-ola de Geriatría y Gerontología. 1993; 28(1):32-40.

15. Guralnik JM, Simonsick EM. 1 Physical disability in older Americans. Journal of Gerontology. 1993; 48(Special_Issue):3-10.

16. Lawton MP. The functional assessment of elderly people. Journal of the American Geriatrics Society. 1971; 19(6):465-81. https://doi.org/10.1111/j.1532-5415.1971.tb01206.x PMid:5094650

17. Ottenbacher KJ, Ostir GV, Peek MK, Snih SA, Raji MA, Markides KS. Frailty in older mexican americans. Journal of the American Geriatrics Society. 2005; 53(9):1524-31. <u>https://doi.org/10.1111/j.1532-5415.2005.53511.x</u> PMid:16137282 PMCid:PMC1388072

18. Lee RC, Wang Z, Heo M, Ross R, Janssen I, Heymsfield SB. Total-body skeletal muscle mass: development and crossvalidation of anthropometric prediction models–. The American journal of clinical nutrition. 2000; 72(3):796-803. PMid:10966902

19. Rech CR, Dellagrana RA, Marucci MD, Petroski EL. Validity of anthropometric equations for the estimation of muscle mass in the elderly. Revista Brasileira de Cineantropometria & Desempenho Humano. 2012; 14(1):23-31.

20. Delmonico MJ, Harris TB, Lee JS, Visser M, Nevitt M, Kritchevsky SB, Tylavsky FA, Newman AB. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. Journal of the American Geriatrics Society. 2007; 55(5):769-74. https://doi.org/10.1111/j.1532-5415.2007.01140.x PMid:17493199

21. Newman AB, Kupelian V, Visser M, Simonsick E, Goodpaster B, Nevitt M, Kritchevsky SB, Tylavsky FA, Rubin SM, Harris TB. Sarcopenia: alternative definitions and associations with lower extremity function. Journal of the American Geriatrics Society. 2003; 51(11):1602-9. <u>https://doi.org/10.1046/j.1532-5415.2003.51534.x</u> PMid:14687390

22. Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, Corsi AM, Rantanen T, Guralnik JM, Ferrucci L. Ageassociated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. Journal of applied physiology. 2003; 95(5):1851-60.

https://doi.org/10.1152/japplphysiol.00246.2003 PMid:14555665

23. Gómez JF, Curcio CL, Alvarado B, Zunzunegui MV, Guralnik J. Validity and reliability of the Short Physical Performance Battery (SPPB): a pilot study on mobility in the Colombian Andes. Colombia medica. 2013; 44(3):165-71. PMid:24892614 PMCid:PMC4002038

24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research. 1975; 12(3):189-98. https://doi.org/10.1016/0022-3956(75)90026-6

25. Icaza MG, Albala C. Minimental State Examinations (MMSE) del estudio de demencia en Chile: análisis estadístico. InOPS. Investigaciones en Salud Pública Documentos Técnicos 1999 Apr (Vol. 7). Organización Panamericana de la Salud.

26. Baker FM, Espino Dv. A spanish version of the geriatric

depression scale in mexican-american elders. International Journal of Geriatric Psychiatry. 1997; 12(1):21-5.

bhttps://doi.org/10.1002/(SICI)1099-1166(199701)12:1<21::AID-GPS444>3.0.CO;2-2

27. Tanimoto Y, Watanabe M, Sun W, Hirota C, Sugiura Y, Kono R, Saito M, Kono K. Association between muscle mass and disability in performing instrumental activities of daily living (IADL) in community-dwelling elderly in Japan. Archives of gerontology and geriatrics. 2012; 54(2):e230-3.

https://doi.org/10.1016/j.archger.2011.06.015 PMid:21831461

28. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among the elderly in New Mexico. American journal of epidemiology. 1998; 147(8):755-63.

://doi.org/10.1093/oxfordjournals.aje.a009520 PMid:9554417

29. Melton LJ, Khosla S, Crowson CS, O'connor MK, O'fallon WM, Riggs BL. Epidemiology of sarcopenia. Journal of the American Geriatrics Society. 2000; 48(6):625-30. https://doi.org/10.1111/j.1532-5415.2000.tb04719.x

PMid 10855597

30. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. Journal of the American Geriatrics Society. 2002; 50(5):889-96. 2-5415 50216 x PMid:12028177 https://doi.org/10.1046/i.153

31. Janssen I. Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. Journal of the American Geriatrics Society. 2006; 54(1):56-62. https://doi.org/10.1111/j.1532-5415.2005.00540.x PMid:16420198

32. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. American journal of epidemiology. 2004; 159(4):413-21. https://doi.org/10.1093/aie/kwh058 PMid:14769646

33. Rolland Y, Czerwinski S, Van Kan GA, Morley JE, Cesari M, Onder G, Woo J, Baumgartner R, Pillard F, Boirie Y, Chumlea WM. Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. The Journal of Nutrition Health and Aging. 2008; 12(7):433-50. https://doi.org/10.1007/BF02982704

34. Delmonico MJ, Harris TB, Lee JS, Visser M, Nevitt M, Kritchevsky SB, Tylavsky FA, Newman AB. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. Journal of the American Geriatrics Society. 2007; 55(5):769-74. https://doi.org/10.1111/i.1532-5415.2007.01140.x PMid:17493199

35. Tanimoto Y, Watanabe M, Sun W, Tanimoto K, Shishikura K, Sugiura Y, Kusabiraki T, Kono K. Association of sarcopenia with functional decline in community-dwelling elderly subjects in Japan. Geriatrics & gerontology international. 2013; 13(4):958-63. https://doi.org/10.1111/ggi.12037 PMid:23452074

36. Cesari M. Rolland Y. Abellan Van Kan G. Bandinelli S. Vellas B, Ferrucci L. Sarcopenia-related parameters and incident disability in older persons: results from the "invecchiare in Chianti" study. Journals of Gerontology Series A: Biomedical Sciences and

Medical Sciences. 2014; 70(4):457-63. https://doi.org/10.1093/gerona/glu181 PMid:25320055 PMCid:PMC4375415

37. Gariballa S, Alessa A. Sarcopenia: prevalence and prognostic significance in hospitalized patients. Clinical nutrition. 2013; 32(5):772-6. https://doi.org/10.1016/j.clnu.2013.01.010 PMid:23395102

38. Rossi AP, Fantin F, Micciolo R, Bertocchi M, Bertassello P, Zanandrea V, Zivelonghi A, Bissoli L, Zamboni M. Identifying sarcopenia in acute care setting patients. Journal of the American Medical Directors Association. 2014; 15(4):303-e7. https://doi.org/10.1016/j.jamda.2013.11.018n PMid:24508329

39. Muscaritoli M, Lucia S, Molfino A. Sarcopenia in critically ill patients: the new pandemia. Minerva anestesiologica. 2013; 79(7):771-7. PMid:23370125

40 Senior HE, Henwood TR, Beller EM, Mitchell GK, Keogh JW. Prevalence and risk factors of sarcopenia among adults living in nursing homes. Maturitas. 2015; 82(4):418-23. doi.org/10.1016/j.maturitas.2015.08.006 PMid:26341045

41. Landi F, Liperoti R, Fusco D, Mastropaolo S, Quattrociocchi D, Proia A, Russo A, Bernabei R, Onder G. Prevalence and risk factors of sarcopenia among nursing home older residents. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2011; 67(1):48-55.

42. Velázquez Alva MD, Irigoyen Camacho ME, Delgadillo Velázquez J, Lazarevich I. The relationship between sarcopenia, undernutrition, physical mobility and basic activities of daily living in a group of elderly women of Mexico City. Nutricion hospitalaria. 2013;28(2).

43. Cruz-Jentoft AJ, Landi F, Schneider SM, Zú-iga C, Arai H, Boirie Y, Chen LK, Fielding RA, Martin FC, Michel JP, Sieber C. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age and ageing. 2014; 43(6):748-59. https://doi.org/10.1093/ageing/afu115 PMid:25241753 PMCid:PMC4204661

44. Cuesta F, Formiga F, Lopez-soto A, Masanes F, Ruiz D, Artaza I, Salvà A, Serra-Rexach JA, Rojano I Luque X, Cruz-Jentoft AJ. Prevalence of sarcopenia in patients attending outpatient geriatric clinics: the ELLI study. Age and ageing. 2015; 44(5):807-9. https://doi.org/10.1093/ageing/afv088 PMid:26220989

45. Beaudart C, Reginster JY, Slomian J, Buckinx F, Locquet M, Bruyère O. Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. J Musculoskelet Neuronal Interact. 2014; 14(4):425-31. https://doi.org/10.1016/S1878-7649(14)70510-8

46. Landi F, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, Bernabei R, Onder G. Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clinical nutrition. 2012; 31(5):652-8. https://doi.org/10.1016/j.clnu.2012.02.007 PMid:22414775